ANTARES PHARMA WKN: 903128 ISIN: US0366421065 Kürzel: ATRS Forum: Aktien Thema: Hauptdiskussion

👍

Läuft endlich mal, geil 🤩

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader https://www.prnewswire.com/news-releases/halozyme-to-acquire-antares-pharma-to-create-a-specialty-product-and-drug-delivery-leader-301524604.html

Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy https://www.globenewswire.com/news-release/2022/03/29/2411744/35385/en/Antares-Pharma-Announces-FDA-Approval-Of-TLANDO-an-Oral-Treatment-for-Testosterone-Replacement-Therapy.html Commercial launch expected in 2Q 2022

Die Entscheidung ist jetzt da

Ende der Woche oder Anfang nächster Woche fällt die Entscheidung

Antares Pharma Non-GAAP EPS of $0.02 beats by $0.01, revenue of $48.73M beats by $1.54M https://seekingalpha.com/news/3808993-antares-pharma-non-gaap-eps-of-0_02-beats-0_01-revenue-of-48_73m-beats-1_54m Antares Pharma press release (NASDAQ:ATRS): Q4 Non-GAAP EPS of $0.02 beats by $0.01. Revenue of $48.73M (+10.5% Y/Y) beats by $1.54M. The Company today provided its full-year 2022 revenue guidance range of $200 to $220 million, which does not include any unapproved products and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Excluding 2021 OTREXUP® proprietary revenue, the guidance range represents a 18% to 30% year-over-year growth rate vs. $211.38M consensus.

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results https://www.globenewswire.com/news-release/2022/03/03/2396099/35385/en/Antares-Pharma-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-and-Operating-Results.html Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million